Who is suitable for vaccination? The world’s first human papillomavirus (HPV) vaccine, which was revealed in 2006, was used to prevent disease caused by four HPV virus subtypes – 6, 11, 16 and 18. Two years ago, Jadaxiu was upgraded – Jadaxiu 9 was revealed, containing five new HPV subtypes – 31, 33, 45, 52 and 58 – in addition to the original quadrivalent HPV vaccine, which can prevent nine HPV subtypes. The data summary and analysis of Jadaxiu’s registration clinical trials in China have all been completed. How powerful are the three vaccines? A six-year-long clinical trial of Cialis in China enrolled more than 6,000 subjects in separate vaccination and control. The results showed that the vaccine was highly effective in preventing certain oncogenic HPV-associated cervical diseases. The results are consistent with data from global clinical studies. In June 2016, a global systematic study of 58 relevant papers from nine countries over a 10-year period showed that the presence of Gadaxu was effective in reducing the incidence of genital warts, Pap smear abnormalities, and precancerous cervical lesions caused by related viral subtypes.